Supplementary Figures 1 through 6 from Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF&lt;sup&gt;V600E&lt;/sup&gt; Melanoma